ClinicalTrials.gg

Program

TSL2109

A development code. Also written as “Treatment arm: TSL2109 capsules。Oral administration。”.

Its studies are mostly in Prostatic Neoplasms, led by China Resources Pharmaceutical Group.

Furthest: phase 1, since Feb 25, 20261 company-led study, 1 open or runningNext primary completion: Dec 31, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
China Resources Pharmaceutical Group11 open or runningphase 1since Feb 25, 2026Feb 25, 2026Dec 31, 2026phase 1 · NCT07514065

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 25, 2026First study: phase 1 study in Metastatic Castration-Resistant Prostate Cancer PatientsFirst studyNCT07514065 · 78 planned · China

Ahead

  1. Dec 31, 2026Primary completion: phase 1 study in Metastatic Castration-Resistant Prostate Cancer PatientsNCT07514065

TargetBeta

CDK4 →read by rule
“TSL2109 is a novel CDK4/6-DYRK2 dual-target inhibitor developed by Jiangsu Tasly Diyee Pharmaceutical Co., Ltd.”study text, by rule · the study

Other programs on CDK4

ProgramCompanyFurthest phaseStudies
abemaciclibruleEli Lillyphase 449
palbociclibrulePfizerphase 436
trilaciclibrulePharmacosmosphase 414
atirmociclibPfizerphase 317
culmerciclibSino Biopharmaceuticalphase 311
HRS-6209Jiangsu HengRui Medicinephase 37
CDK4 Inhibitor BGB-43395ruleBeOne Medicinesphase 34
narazaciclibrulehangzhou-hanx-biopharmaceuticals-ltdphase 24
vustanaciclibregor-pharmaceuticals-incphase 23
CG-7321rulechengdu-cynogen-bio-pharmaceutical-tech-co-ltdphase 11
nkt5097 cdk2rulenikang-therapeutics-incphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07514065Metastatic Castration-Resistant Prostate Cancer Patients · China1RecruitingDec 31, 202678

How it is read

Names in the registry

  • “Treatment arm: TSL2109 capsules。Oral administration。”, 1 entry

Codes read as this program: TSL2109.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.